There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa.
Ryan Scott
Advertisement
Ryan Scott is an Associate Editor of CURE; she joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages CURE's social media accounts; check us out @curetoday across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@mjhlifesciences.
Articles by Ryan Scott
Advertisement
Advertisement
Advertisement